At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.
|Videos|November 11, 2022
Dr. Diana Bowen on welcoming gender-diverse patients in the urology practice
Author(s)Urology Times staff
“Don't make assumptions about any patients,” says Diana K. Bowen, MD.
Advertisement
In this interview, Diana K. Bowen, MD, discusses ways to make gender-diverse patients feel welcome in practices. Bowen is an assistant professor of urology at Northwestern University Feinberg School of Medicine. She was interviewed at the
Advertisement
Related to this article
Take a look through some of the notable data presentations at this year's ESMO Congress.
Advertisement
Advertisement
Trending on Urology Times
1
Darolutamide associated with less cognitive change than enzalutamide in prostate cancer
2
ESMO 2026: Key presentations across genitourinary oncology
3
KLK2-comPAS trial explores dual T-cell engagement in mCRPC
4
Gedatolisib plus darolutamide shows preliminary activity in mCRPC
5